Skip to main content
. 2020 Dec 30;13(1):91. doi: 10.3390/cancers13010091

Figure 1.

Figure 1

CONSORT diagram of MMAIT-Stage IV patients from the phase III randomized double-blinded international multi-center trial. The flow diagram describing the MMAIT-IV (NCT00052156) trial, is shown. Selected patients (n = 92) from MMAIT-IV trial were used as a pilot study cohort. MMAIT = Malignant Melanoma Active Immunotherapy Trial; SLN = Sentinel Lymph Node; PBL = Peripheral Blood Leukocytes; SNP = Single Nucleotide Polymorphism.